We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

38 hedge funds and large institutions have $172M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

93% more capital invested

Capital invested by funds: $88.9M → $172M (+$83M)

27% more funds holding

Funds holding: 30 → 38 (+8)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
38
Holders Change
+8
Holders Change %
+26.67%
% of All Funds
0.61%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
6
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
+$22.4M
2
DM
Deerfield Management
New York
+$11.1M
3
PA
Perceptive Advisors
New York
+$10.9M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$10.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.83M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$6.3M
2
O
OrbiMed
New York
-$402K
3
Renaissance Technologies
Renaissance Technologies
New York
-$74K
4
LSA
Leonteq Securities AG
Switzerland
-$70.9K
5
SCM
Sio Capital Management
New York
-$56.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Tekla Capital Management
Massachusetts
$164K – – –
Two Sigma Advisers
27
Two Sigma Advisers
New York
$135K +$141K +35,900 New
LSA
28
Leonteq Securities AG
Switzerland
$132K -$70.9K -18,000 -34%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$94.8K – – –
SSA
30
Schonfeld Strategic Advisors
New York
$49.4K +$51.6K +13,100 New
VF
31
Virtu Financial
New York
$49K +$51.5K +13,084 New
BlackRock
32
BlackRock
New York
$31.1K – – –
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$8K +$5.33K +1,353 +159%
TWC
34
TD Waterhouse Canada
Ontario, Canada
$2.63K -$689 -175 -20%
S
35
SignatureFD
Georgia
$1.13K – – –
Simplex Trading
36
Simplex Trading
Illinois
$1K +$1.81K +459 New
Osaic Holdings
37
Osaic Holdings
Arizona
$113 – – –
B
38
Braidwell
Connecticut
– -$6.3M -2,000,000 Closed
Renaissance Technologies
39
Renaissance Technologies
New York
– -$74K -23,500 Closed
Citadel Advisors
40
Citadel Advisors
Florida
– -$39.4K -12,510 Closed
TC
41
Truvestments Capital
Florida
– -$1.05K -335 Closed
1
2

FUSN Hedge Fund Activity: Q1 2023 in Review

38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2023, worth a combined $172M — up 93% from $88.9M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new FUSN positions and 4 closed out — a net gain of 8 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $22.4M. The largest seller was Braidwell, exiting entirely with an estimated $6.3M sold.

  • 38 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2023, up from 30 in Q4 2022.
  • Funds reported $172M of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2023, up 93% quarter-over-quarter.
  • 12 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2023 and 4 closed out, a net change of +8 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2023 was Avidity Partners Management, an estimated $22.4M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2023 was Braidwell, an estimated $6.3M sold.

Based on aggregated 13F filings for Q1 2023.